Alnylam Exec出售股份,但仍是生物制药公司的主要利益攸关方。 Alnylam exec sells shares, but remains a major stakeholder in the biopharmaceutical firm.

Kevin Joseph Fitzgerald, Alnylam制药公司执行副总裁,最近出售了该公司股票的股份。 Kevin Joseph Fitzgerald, Executive Vice President of Alnylam Pharmaceuticals, recently sold shares of the company's stock. 菲茨杰拉德尽管被卖了 却依然是一个重要的股东 Despite the sale, Fitzgerald remains a significant shareholder. Alnylam是一家专门从事RNA干预的生物制药公司,投资者兴趣与分析者评分不一。 Alnylam, a biopharmaceutical company specializing in RNA interference, has seen mixed investor interest and analyst ratings. 该公司的股票价格波动不定,12个月最高,为304.39美元,最低,为141.98美元。 The company's stock price has fluctuated, with a 12-month high of $304.39 and a low of $141.98. 尽管高管最近销售股票,但Alnylam公司继续受到市场密切监视。 Despite recent stock sales by executives, Alnylam continues to be watched closely by the market.